- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05773053
Un estudio de las dosis de NT 201 en el tratamiento de la prominencia del platisma (PAOLA)
Un estudio prospectivo, doble ciego, aleatorizado, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de las dosis de NT 201 en el tratamiento de la prominencia del platisma
The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20037
- Merz Investigation Site #0010170
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Merz Investigational Site #0010453
-
Coral Gables, Florida, Estados Unidos, 33143
- Merz Investigation Site #0010470
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Merz Investigation Site #0010105
-
-
New Jersey
-
Verona, New Jersey, Estados Unidos, 07044
- Merz Investigation Site #0010471
-
-
New York
-
New York, New York, Estados Unidos, 10022
- Merz Investigation Site #0010469
-
New York, New York, Estados Unidos, 10028
- Merz Investigation Site #0010405
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Presence of four (medial and lateral, left and right) prominent platysmal bands
- Moderate to severe platysmal bands as assessed by the investigator and subject on the MAPS-D at maximum contraction
Exclusion Criteria:
- Any serious disease or disorder (medical or psychiatric) that could interfere with the safe completion of treatment or compromise subject safety
- Botulinum toxin treatment in the face (below the lower orbital rim), neck, or chest within the last 12 months prior to study treatment
- History of lower face surgery, neck or chest surgery, aesthetic procedures (e.g., ablative skin resurfacing, laser, chemical peel, micro-focused ultrasound, deoxycholic acid injections, micro-needling, non-surgical fat reduction procedure), and orthodontic procedures (e.g., braces) in the 12 months prior to study treatment
- Previous use of any permanent (non-biodegradable) or semi-permanent (e.g., calcium hydroxylapatite, poly-L-lactic acid, polymethyl methacrylate, etc.) facial tissue augmentation therapy, lifting sutures, permanent implants or autologous fat to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 24 months prior to study treatment
- Previous use of any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy to the lower face (i.e., below the level of the bottom of the nose), neck, or chest within 12 months prior to study treatment
- Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including myasthenia gravis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function
- Female of childbearing potential not using a highly effective method of birth control, planning to get pregnant, or pregnant or lactating
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: NT 201 Dose 1
Subjects will receive Dose 1. |
Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.
Otros nombres:
|
|
Experimental: NT 201 Dose 2
Subjects will receive Dose 2. |
Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.
Otros nombres:
|
|
Experimental: NT 201 Dose 3
Subjects will receive Dose 3. |
Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.
Otros nombres:
|
|
Comparador de placebos: Placebo
Subjects will receive matching placebo. |
NT 201 Matching-placebo. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2
Periodo de tiempo: Baseline and Week 2
|
The platysma area was assessed live by the investigator at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements. |
Baseline and Week 2
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2
Periodo de tiempo: Baseline and Week 2
|
The platysma area was assessed live by the subject at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements. |
Baseline and Week 2
|
|
Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: From first dose of study drug up to Week 17
|
TEAEs were defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment. An TEAE was considered to be "related" to IP(s) if a causal relationship between the IP(s) and an TEAE was at least a reasonable possibility (i.e., the relationship cannot be ruled out). |
From first dose of study drug up to Week 17
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Merz Medical Expert, Merz North America, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- M602011078
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .